July 19, 2021
Shionogi said on July 16 that its cancer peptide vaccine S-588410 failed to hit the primary goal in a Japan PIII study as a postoperative adjuvant therapy in patients with esophageal cancer. The vaccine has been licensed from Kanagawa-based OncoTherapy...read more